Literature DB >> 36175614

Live Birth Rates in Women Under 38 Years Old with AMH Level < 1.2 ng/ml in the First In Vitro Fertilization + / - Intracytoplasmic Sperm Injection: Retrospective Study and Arguments for Care.

Karine Morcel1, Philippe Merviel2, Diane Pertuisel1, Pandora James1, Sarah Bouée1, Mathilde Le Guillou1, Jean-Jacques Chabaud1, Sylvie Roche1, Hortense Drapier3, Aurore Perrin3, Damien Beauvillard3.   

Abstract

Many studies failed to show a predictive impact of AMH levels on the chances of pregnancy; however, acceptable pregnancy rates for young women with low AMH levels were observed in IVF + / - ICSI. The objectives of this retrospective study were to evaluate the clinical pregnancy and live birth rates in the first IVF + / - ICSI cycle in women under 38 years old with AMH level < 1.2 ng/ml and to determine the arguments for care. We classified the women into three groups: group A: AMH < 0.4 ng/ml (n: 86); group B: AMH: 0.4 to 0.8 ng/ml (n: 90); and group C: AMH > 0.8 to < 1.2 ng/ml (n: 92). We recorded data on the patients' characteristics, stimulation cycles, embryo cultures, and ongoing pregnancies. No difference was observed between the three groups for the number of embryos transferred, the clinical pregnancy, and the live birth rates (LBR) per embryo transfer (LBR/transfer: 24.1% in group A, 25.9% in group B, and 28.1% in group C). The young age of the women reassures about the oocyte quality, but a low level of AMH may raise concerns about a lower quantitative oocyte yield, leading to accelerated management of the couple in IVF + / - ICSI.
© 2022. The Author(s), under exclusive licence to Society for Reproductive Investigation.

Entities:  

Keywords:  Anti-Müllerian hormone; In vitro fertilization/intracytoplasmic sperm injection; Live birth; Predictive factors; Pregnancy

Year:  2022        PMID: 36175614     DOI: 10.1007/s43032-022-01091-x

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   2.924


  48 in total

Review 1.  Anti-Müllerian hormone and ovarian dysfunction.

Authors:  Frank J Broekmans; Jenny A Visser; Joop S E Laven; Simone L Broer; Axel P N Themmen; Bart C Fauser
Journal:  Trends Endocrinol Metab       Date:  2008-09-18       Impact factor: 12.015

2.  The origin and impact of embryonic aneuploidy.

Authors:  Elpida Fragouli; Samer Alfarawati; Katharina Spath; Souraya Jaroudi; Jonas Sarasa; Maria Enciso; Dagan Wells
Journal:  Hum Genet       Date:  2013-04-26       Impact factor: 4.132

3.  ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria.

Authors:  A P Ferraretti; A La Marca; B C J M Fauser; B Tarlatzis; G Nargund; L Gianaroli
Journal:  Hum Reprod       Date:  2011-04-19       Impact factor: 6.918

Review 4.  Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).

Authors:  A La Marca; G Sighinolfi; D Radi; C Argento; E Baraldi; A Carducci Artenisio; G Stabile; A Volpe
Journal:  Hum Reprod Update       Date:  2009-09-30       Impact factor: 15.610

Review 5.  Is AMH a regulator of follicular atresia?

Authors:  David B Seifer; Zaher Merhi
Journal:  J Assist Reprod Genet       Date:  2014-09-06       Impact factor: 3.412

6.  Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition.

Authors:  Ilse A J van Rooij; Isolde den Tonkelaar; Frank J M Broekmans; Caspar W N Looman; Gabrielle J Scheffer; Frank H de Jong; Axel P N Themmen; Egbert R te Velde
Journal:  Menopause       Date:  2004 Nov-Dec       Impact factor: 2.953

7.  A validated model of serum anti-müllerian hormone from conception to menopause.

Authors:  Thomas W Kelsey; Phoebe Wright; Scott M Nelson; Richard A Anderson; W Hamish B Wallace
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

8.  The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome.

Authors:  Peter Humaidan; Carlo Alviggi; Robert Fischer; Sandro C Esteves
Journal:  F1000Res       Date:  2016-12-23

Review 9.  The physiology and clinical utility of anti-Mullerian hormone in women.

Authors:  Didier Dewailly; Claus Yding Andersen; Adam Balen; Frank Broekmans; Nafi Dilaver; Renato Fanchin; Georg Griesinger; Tom W Kelsey; Antonio La Marca; Cornelius Lambalk; Helen Mason; Scott M Nelson; Jenny A Visser; W Hamish Wallace; Richard A Anderson
Journal:  Hum Reprod Update       Date:  2014-01-14       Impact factor: 15.610

10.  Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection.

Authors:  J V Jeppesen; R A Anderson; T W Kelsey; S L Christiansen; S G Kristensen; K Jayaprakasan; N Raine-Fenning; B K Campbell; C Yding Andersen
Journal:  Mol Hum Reprod       Date:  2013-04-04       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.